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Background. T-box expressed in T cells (TBET) and guanine adenine thymine adenine sequence-binding protein 3 (GATA3) play
important roles in the differentiation of Th1 and Th2 subsets, which contributes to the progression of acute coronary syndrome
(ACS). Objective. This study aimed to investigate the temporal change of TBET/GATA3 mRNA ratio in ACS. Methods. Thirty-
three patients suspected of ACS with symptom onset within 24 hours were recruited. Blood samples were taken after arrival at the
emergency department and at hourly intervals until the 6th hour.ThemRNA expressions of TBET andGATA3were quantified by a
real-time RT-qPCR. Results.The TBET/GATA3mRNA ratio was elevated dramatically in patients with acute myocardial infarction
(AMI) and exhibited biphasic M-shaped release kinetics with two distinct peaks. The ratio was elevated 2 hours after symptom
onset, dropped to the lowest level at 10 hours, and rose to the second peak at 14 hours. A similar biphasic M-shaped curve was
observed in AMI patients with blood samples taken prior to any intervention. Conclusions. The TBET/GATA3 mRNA ratio was
elevated in AMI patients throughout most of the first 20 hours after symptom onset. The biphasic M-shaped release kinetics was
more likely to reflect pathophysiological changes rather than treatment effects.
1. Introduction
On activation, T lymphocytes differentiate into T-helper (Th)
1 and Th2 subsets, and although the control of the Th1/Th2
imbalance is not fully elucidated, there is growing evidence to
suggest that two transcription factors, T-box expressed in
T cells (TBET) and guanine adenine thymine adenine
sequence-binding protein 3 (GATA3), play important roles in
such differentiation [1–4].
Th1 is essential in the process of plaque instability and
plaque rupture, which in turn are common features in the
pathogenesis of acute coronary syndrome (ACS) [5–7]. Up-
regulation of Th1 response has been demonstrated in the cir-
culating lymphocytes of patients with ACS [6, 8]. In contrast,
Th2 has rarely been shown in atherosclerotic lesions. Recent
studies suggest that loss of Th1 and Th2 balance contributes
to plaque rupture and the onset of ACS [6, 9]. Th1 and Th2
imbalances in the pathogenesis of ACS have been observed
coherently from transcription to protein levels in both animal
models and human subjects [8–13].The relative expression of
TBET andGATA3, resulting in a swing in theTh1/Th2pendu-
lum, has been implicated in several immunological diseases
and may provide better prognostic and diagnostic informa-
tion than downstream cytokines.
In our recent study, we have demonstrated that the TBET/
GATA3 mRNA ratio was elevated in patients with ACS and
associated with disease severity [14]. However, little is known
about whether the biological and temporal changes in circu-
lating leukocyte TBET/GATA3mRNA balance are associated
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with the ACS progress and whether the changes reflect the
development of the pathophysiological processes or the effect
of therapeutic intervention. This study aimed to investigate
the temporal dynamic changes in initial mRNA expressions
of TBET/GATA3 ratio in patients presenting with various
clinical stages of coronary artery diseases including stable
angina (SA), unstable angina (UA), and acute myocardial
infarction (AMI).
2. Materials and Methods
2.1. Study Design and Setting. This prospective observational
study was conducted at the Emergency Department (ED) of
the Prince of Wales Hospital in Hong Kong. Ethical approval
was obtained from the local Institutional Review Board, and
written consent was obtained from all patients or the clos-
est available relative. Patients were recruited consecutively
between 9:00 a.m. and 5:00 p.m. fromMonday to Friday. Age-
and sex-matched healthy subjects, which acted as a healthy
control group, had no history of chronic or recent acute
illness. Both the research nurse who collected clinical data
and the scientist who performed the laboratory analysis were
blinded to the clinical outcome.
2.2. Inclusion and Exclusion Criteria. Patients aged ≥18 years
presenting to the ED with nontraumatic chest or epigastric
pain of less than 24 hours since acute symptom onset, and
with a provisional diagnosis of ACS were recruited into the
study. Patients were excluded if they had sustained an AMI
within 10 days prior to arrival, had received an intramuscular
injection or sustained traumawithin 3 days, had renal impair-
ment, severemuscular or infectious disease, asthma, systemic
lupus erythematosus, or obvious noncardiac chest pain (e.g.,
pneumothorax, rib fractures, pneumonia, or trauma).
2.3. Diagnosis and Treatment. Patients were diagnosed as SA
(a disease control group) if there was a typical chest pain
occurring with activity but relieved by rest or vasodilators
within 10 minutes of onset. ACS patients were diagnosed
according to the published consensus of the European Society
of Cardiology and American College of Cardiology Commit-
tee at the time of the study [15, 16]. Patients were diagnosed
as (i) UA patient (a disease control group) if there was an
accelerating or “crescendo” pattern of chest pain which either
occurred at rest or lasted longer than 10 minutes or was
not responsive to medication; (ii) AMI patient if there was
an increase in cardiac troponin T (cTnT) with at least one
value above 0.06𝜇g/L together with evidence of myocardial
ischemia with at least one of the following: (a) symptoms of
ischemia (chest pain); (b) electrocardiogram (ECG) changes
indicative of new ischemia (new ST-T changes or new left
branch bundle block (LBBB) or T wave inversion); (c) devel-
opment of pathological Q wave changes in ECG; (d) echo
evidence of new loss of viable myocardium or new regional
wallmotion abnormality [16]. AMI patients were further sub-
divided into patients with ST elevation myocardial infarction
(STEMI) and non-ST elevation MI (NSTEMI). Patients were
managed according to the standardized treatment protocols
[15, 17] and treated with aspirin, nitrates, enoxaparin, throm-
bolysis, and/or coronary angiography, and percutaneous
coronary intervention (PCI) as clinically indicated.
2.4. Blood Collection, Processing, and Storage. A 12mL of
venous blood sample was withdrawn from each patient as
soon as possible after arrival at the ED (𝑇
0
) and at hourly
intervals until the 6th hour (𝑇
1
, 𝑇
2
, 𝑇
3
, 𝑇
4
, 𝑇
5
, and 𝑇
6
) and
then immediately transferred into EDTA tubes. A venous
blood sample was also withdrawn from each control subject
at 𝑇
0
, 𝑇
3
, and 𝑇
6
after written consent was obtained.
After centrifugation at 1600 g for 10 minutes at 4∘C, the
buffy coat layer was transferred to amicrocentrifuge tube and
further centrifuged at 230 g for 5 minutes at 4∘C to remove
the plasma.Then, the buffy coat was removed, lysed, and pre-
served in lysis buffer (Trizol LSReagent, Invitrogen).The total
RNA in the samples was extracted by the RNeasy Mini Kit
(Qiagen Inc., Canada) following manufacturer’s instructions.
All RNA samples were pretreated with Amplification Grade
Deoxyribonuclease I (Invitrogen) and then stored at −80∘C
until further processing. Blood samples were also collected
for routine measurement of cTnT and other biochemical
parameters.The upper reference limit for cTnTwas 0.03𝜇g/L.
2.5. Real-Time Quantitative Reverse Transcription Polymerase
Chain Reaction (RT-qPCR). A quantitative RT-qPCR by
the ABI Prism 7700 Sequence Detector System (Applied
Biosystems, Foster City, CA, USA) was used to determine
the mRNA expressions of TBET, GATA3, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) which was used as
a housekeeping gene for normalization. We have developed
RT-qPCR assays for TBET (Gene ID: 30009) and GATA3
(Gene ID: 2625). The assay for TBET spans exons 1 and
2 of the transcript located on 17q21.32 and the assay for
GATA3 spans exons 2 and exon 3 of the transcript located
on 10p15. Both assays are intron-spanning. The primer
and probe sequences of TBET, GATA3, and GAPDH were
designed using Primer Express (v2.0) and are summarized
in Supplemental Table 1 (see Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2013/139895). The RT-
qPCR amplifications were performed in a volume of 25𝜇L
at 50∘C for 2 minutes, 60∘C for 30 minutes, and 95∘C for 5
minutes followed by 40 cycles of 94∘C for 20 seconds and
60∘C for 1 minute. Each sample was run in duplicate. The
results of RT-qPCRwere analyzed by the Sequence Detection
Software version 1.9 (Applied Biosystems, Foster City, CA,
USA). Calibration curves for TBET, GATA3 and GAPDH
mRNA measurements were prepared by serial dilutions of
HPLC-purified single-stranded synthetic oligonucleotides.
The concentrations of TBET and GATA3 mRNA were
expressed in copies/pg of GADPHmRNA.
2.6. Statistical Analysis. Statistical analysis was performed
using MedCalc version 11.5.1 (Mariakerke, Belgium) and
Statview for Windows version 5.0 Statistical Analysis Soft-
ware (Abacus Concepts, SAS Institute, Cary, NC, USA). Cat-
egorical variables were compared using Chi-square test. Con-
tinuous variables were compared by using Mann-Whitney
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Table 1: Baseline characteristics of AMI and non-AMI patients.
Total (𝑛 = 33) Non-AMI (𝑛 = 19) AMI (𝑛 = 14) 𝑃 Value
Characteristic
Age-median years (IQR) 73 (56–81) 74 (55–83) 65 (56–81) 0.477
Male gender—no. (%) 20 (58) 10 (53) 9 (64) 0.754
Time from symptom onset to blood taking for
measurements of TBET & GATA3—median hours (IQR) 4.0 (3.0–8.9) 3.5 (2.6–5.8) 5.3 (4.0–12.0) 0.068
Past history—no. (%)
Myocardial infarction 5 (15) 2 (11) 2 (14) 0.832
Cerebrovascular disease 7 (21) 4 (21) 3 (21) 0.686
Heart failure 6 (18) 4 (21) 1 (7.0) 0.542
Diabetes 11 (33) 4 (21) 6 (43) 0.335
Hypertension 21 (64) 11 (58) 9 (64) 0.991
Current smoker 9 (27) 5 (26) 4 (29) 0.801
Ex-smoker 3 (24) 0 (0.0) 2 (14) 0.336
Obesity 6 (18) 1 (5.0) 4 (29) 0.176
Hyperlipidemia 6 (18) 2 (11) 4 (29) 0.383
Atrial fibrillation 4 (12) 3 (16) 1 (7) 0.832
Medications—no. (%)
Warfarin 2 (6.0) 2 (5.9) 0 (0.0) 0.607
Aspirin 15 (46) 9 (47) 6 (17.6) 0.923
Beta-blocker 9 (33) 4 (21) 4 (11.8) 0.931
Final diagnosis—no. (%)
Stable angina 8 (24) 8 (42) —
Unstable angina 11 (33) 11 (58) —
NSTEMI 5 (15) — 5 (36)
STEMI 9 (27) — 9 (64)
Mortality—no. (%) 2 (6.0) 0 (0.0) 2 (14) 0.336
𝑈 test or unpaired 𝑡-test between the two groups, and by using
ANOVA test followed by a post hoc Bonferroni test for mul-
tiple comparisons. A 𝑃 value of less than 0.05 was considered
as statistically significant.
In this pragmatic study, it was important that essential
therapies continued without delay or interruption. Inevitably,
this meant that blood samples could not be taken at some
time points. In order to proceedwith statistical analysis,miss-
ing data points were filled using a statistical technique
described by Snedecor andCochran [18]. 16% of the total data
points were missing and were computed using the following
formula:
𝑋 =
𝑎𝑇 + 𝑏𝐵 − 𝑆
(𝑎 − 1) (𝑏 − 1)
, (1)
where 𝑎 is the number of patients, 𝑏 is the number of time
points, 𝑇 is the sum of data points from the same patient
with missing time point, 𝐵 is the sum of data points from the
same time point as missing time point, and 𝑆 is the sum of all
observed data points.
In order to determine whether the dynamic changes of
the TBET/GATA3 mRNA ratio were related to the treatment
effect or primarily to pathophysiological changes, the changes
of the ratio in 136 patients (47 AMI and 89 non-AMI) with
single blood samples taken at ED arrival were used for com-
parison [14].
3. Results
Between 12 September, 2007 and 12 February, 2008, 33
patients were recruited to the study with a provisional
diagnosis of ACS. Baseline characteristics of the patients
are shown in Table 1. The median age of the 28 healthy
subjects acting as the healthy control group was 58 years
(IQR 53–62), and there were 18 males (64.0%). The 95th
percentile for the TBET/GATA3 mRNA ratio was 1.26 in the
control group. Figure 1 shows the temporal changes of the
TBET/GATA3 mRNA ratio in patients with AMI and non-
AMI over 20 hours from the symptom onset and in healthy
control subjects.The TBET/GATA3mRNA ratios in the AMI
group were significantly higher than those in the non-AMI
group which included patients with SA and UA acting as the
disease control group at 6 hours (1.7 versus 1.1, 𝑃 = 0.007), 8
hours (1.6 versus 1.2, 𝑃 = 0.006), 14 hours (2.8 versus 1.2, 𝑃 =
0.035), 16 hours (2.4 versus 1.2, 𝑃 = 0.020), and almost at 18
hours (1.7 versus 0.8, 𝑃 = 0.060). The TBET/GATA3 mRNA
ratio exhibited biphasic M-shaped release kinetics. The ratio
was elevated 2 hours after the symptom onset, dropped to
the lowest level at 10 hours, and rose to the second peak at
14 hours. The biphasic M-shaped curve was also observed
by plotting the TBET/GATA3 mRNA ratio against the time
from ED arrival (Figure 2). The temporal changes in the
TBET/GATA3 mRNA ratio for each individual patient were
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Figure 1: Temporal changes in the TBET/GATA3 mRNA ratio after
symptom onset in 14 AMI patients (∙), 19 non-AMI patients (I),
and 28 control subjects (󳵳). Data is presented as mean ± 1SEM.
The grey zone represents the ratio within the 95th percentile (i.e.,
≤1.26). Significant difference in TBET/GATA3 mRNA ratio was
found between AMI and non-AMI patients with 𝑃 < 0.05 by using
𝑡-test (∗) or post hoc Bonferroni test (∗∗).
shown in Figure 3. The ratios were above the 95th percentile
in only 2 out of 8 SApatients (25.0%) (Figure 3(a)) while there
were 6 out of 11 UA patients (54.5%) with the ratios above
the 95th percentile (Figure 3(b)). Among the 14AMI patients,
the ratios were above the 95th percentile in all the 9 STEMI
patients (100.0%) (Figure 3(c)) and all the 5 NSTEMI patients
(100.0%) (Figure 3(d)).
The areas below the curves for all the patient groups were
significantly greater than that for the control group (𝑃 <
0.0001). The area below the curve for the STEMI group was
significantly greater than that for the SA group (𝑃 = 0.041)
while for the NSTEMIwas significantly greater than those for
the SA (𝑃 = 0.001) and the UA (𝑃 = 0.008) groups.
Significant difference in TBET/GATA3 mRNA ratio at 𝑇
0
was found across different groups (Kruskal-Wallis Test, 𝑃 =
0.0006) (Figure 4). The median TBET/GATA3 mRNA ratio
was highest in NSTEMI patients (1.97 (IQR: 1.54–3.08)), fol-
lowed by STEMI (1.32 (IQR: 1.19–1.84)), UA (1.18 (IQR: 1.10–
1.33)), and SA (1.05 (IQR: 0.92–1.11)) and lowest in healthy
subjects (0.97 (IQR: 0.65–1.10)).
Based on Figure 1, it was difficult to determine whether
the biphasic M-shaped release kinetics was due to treatment
effects or pathophysiological mechanisms. In order to find
out the underlying reason, it was necessary to investigate
the temporal changes of TBET/GATA3 mRNA ratio in
samples taken prior to any intervention. The first samples
taken from the 33 patients exhibited similar release kinet-
ics as shown in Figure 1. However, the sample size was too
small for robust analysis. Therefore, blood samples taken
from the 136 patients prior to any intervention recruited in
our previous study were investigated [14]. A similar biphasic
M-shaped curve as shown in Figure 5 was observed in the
47 AMI patients. Changes in the TBET/GATA3 mRNA ratio
of the 89 non-AMI patients resembled those of the AMI
patients. The TBET/GATA3 mRNA ratios in the AMI group
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Figure 2: Temporal changes in the TBET/GATA3 mRNA ratio
after ED arrival in 14 AMI patients (∙), 19 non-AMI patients (I),
and 28 control subjects (󳵳). Data is presented as mean ± 1SEM.
The grey zone represents the ratio within the 95th percentile (i.e.,
≤1.26). Significant difference in TBET/GATA3 mRNA ratio was
found between AMI and non-AMI patients with 𝑃 < 0.05 by using
𝑡-test (∗).
were significantly higher than those in the non-AMI group
at 2 hours (1.7 versus 0.9, 𝑃 = 0.001), 4 hours (2.2 versus
1.1, 𝑃 = 0.003), 6 hours (2.0 versus 1.0, 𝑃 = 0.0006), 8
hours (2.2 versus 1.1, 𝑃 = 0.0003), 10 hours (1.9 versus 1.0,
𝑃 = 0.003), 12 hours (1.8 versus 1.0, 𝑃 = 0.011), 14 hours (2.8
versus 1.2, 𝑃 = 0.010), 16 hours (1.7 versus 0.9, 𝑃 = 0.044),
and 20 hours (1.8 versus 1.0, 𝑃 = 0.002).
4. Discussion
The Evidence shows that the progression of atherosclerotic
disease is associated with systemic immune activation [11, 19].
Different stages of atherosclerotic disease are associated with
distinct differentiation patterns of activated T-helper cells.
Many studies have demonstrated that Th1/Th2 imbalance
contributes to the initiation and progression of ACS [6, 9].
Also, there is growing evidence to suggest that two upstream
transcription factors, TBET and GATA3, governing T-helper
cell differentiation, play an important role in the progression
of atherosclerosis and its complications [20–23]. TBET pro-
motes Th1 lineage commitment [24] and maintains the Th1
mediated immune response, which fosters macrophage acti-
vation, infiltration, and the resulting ACS [25]. Th1 cells and
their related cytokines play a crucial role in inflammatory cell
infiltration to the lipid plaque [9–12]. Th1 cytokines were ele-
vated in ACS patients with higher concentrations in AMI
patients compared with SA or UA patients [10]. GATA3 pro-
motes Th2 differentiation [26] and induces Th2 cytokines
production in an analogous way to TBET [27].
In our previous study [14], the diagnostic performances of
initial CK, initial cTnT, GATA3 mRNA, TBET mRNA, and
TBET/GATA3 mRNA ratio were compared using receiver
operating characteristics (ROC) curve analysis. The area
under the curve (AUC) for TBET/GATA3 mRNA ratio
was 0.897 (95% CI 0.833–0.943), which was greater than
that of the other variables analyzed. There were significant
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Figure 3: Continued.
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Figure 3: Temporal changes in TBET/GATA3mRNA ratio in 8 patients with stable angina (a), 11 patients with unstable angina (b), 9 patients
with STEMI (c), and 5 patients with NSTEMI (d). The grey zone represents the ratio within the 95th percentile (i.e., ≤1.26).
differences in the AUC between TBET/GATA3 ratio and ini-
tial CK (0.780; 95% CI 0.700–0.847; 𝑃 = 0.0142), initial cTnT
(0.785; 95% CI 0.705–0.851; 𝑃 = 0.0116), GATA3 mRNA
(0.704; 95% CI 0.643–0.796; 𝑃 = 0.0001), and TBET mRNA
(0.510; 95% CI 0.422–0.597; 𝑃 < 0.0001).
This study was the first to demonstrate distinct temporal
changes of the TBET/GATA3 mRNA ratios in AMI patients,
non-AMI patients, and healthy control subjects. The TBET/
GATA3 mRNA ratio was elevated dramatically in AMI
patients and exhibited biphasic M-shaped release kinetics
with two distinct peaks. The first blood samples taken from
the 14 AMI patients prior to any intervention in the current
study also showed the biphasic M-shaped curve. However,
the sample size was too small for robust analysis and drawing
any conclusion. Therefore, the blood samples taken from the
47 AMI patients prior to any intervention in our previous
study were used for analysis by plotting the change of the
TBET/GATA3 ratio against the symptom onset. A similar
biphasic M-shaped curve was observed. This indicates that
the temporal changes in the TBET/GATA3mRNA ratio were
associated with the development of the pathophysiological
processes rather than the effect of therapeutic intervention.
Besides, the temporal changes of the TBET/GATA3 ratio
in the 89 non-AMI patients recruited in the previous study
resembled those in the AMI patients. However, this was not
observed in the 19 non-AMI patients recruited in the current
study.Thedifferencemay be explained by the difference in the
proportions of the UA and SA patients. With a much higher
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Figure 4: Box-plot of TBET/GATA3 mRNA ratio at 𝑇
0
in healthy
subjects (𝑁 = 28), in patients with stable angina (𝑁 = 8), unstable
angina (𝑁 = 11), NSTEMI (𝑁 = 5), and STEMI (𝑁 = 9). The
differences across the groups were significant (Kruskal-Wallis test,
𝑃 = 0.0006), while the differences between groups are compared
using Mann-Whitney 𝑈 test. The lines inside the boxes denote
medians, while the boxes mark the interval between the 25th and
75th percentiles. The whiskers denote the interval between the 10th
and 90th percentiles.
proportion of UA patients (80.9% versus 57.9%), the curve
shape was much closer to that of AMI patients, but the peaks
were less pronounced compared to those of AMI patients.
The biphasic release kinetics of TBET/GATA3 mRNA
ratio suggested that significant pathophysiological processes
were underway which could reflect a surge in inflamma-
tory and/or immunological activity in ACS. One possible
explanation is that the first peak represents the increased
inflammatory activity associated with plaque rupture and a
distinct Th1 mediated response to coronary arterial inflam-
mation in ACS patients [12]. The second peak may reflect the
active immunological response to myocardial necrosis. The
loss of Th1/Th2 balance in peripheral blood of ACS patients
may represent distinct inflammatory cascades mediating the
myocardial inflammation after myocardial necrosis which
leads to ventricular remodeling [12].
Several studies have shown that Th1/Th2 imbalance is
implicated in the ACS process [6, 9, 12, 28]. This imbalance
is particularly related to more severe ACS and tends to skew
towards Th1 predominance. However, the sampling proce-
dures did not specify exact timings and generally related tim-
ings to ED arrival rather than symptom onset. The more pre-
cise timing of our study allowed a more detailed analysis of
the temporal variations of TBET/GATA3mRNA ratio, which
in turn reflected Th1/Th2 balance in ACS patients. TBET/
GATA3 mRNA ratio may act as an alternative measure of
Th1/Th2 cytokine profiles as the altered Th1/Th2 cytokine
expression in ACS is the result of a shift of TBET and GATA3
profiles. In line with other studies, Th1/Th2 balance was
reflectedmore closely by the TBET/GATA3mRNA ratio than
the variations of absolute TBET andGATA3 expressions [29].
There were two limitations in this study. Firstly, the num-
ber of participants was relatively small. Further studies with
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Figure 5: Temporal changes in mean TBET/GATA3 mRNA ratio
after symptomonset in 47AMIpatients (∙) and 89 non-AMI patients
(I) recruited in our previous study [14]. Data is presented as mean ±
1SEM. The grey zone represents the ratio within the 95th percentile
(i.e., ≤1.26). Significant difference in TBET/GATA3mRNA ratio was
found between AMI and non-AMI patients with 𝑃 < 0.05 by using
𝑡-test (∗) or post hoc Bonferroni test (∗∗).
larger sample sizes are required to investigate the diagnostic
and prognostic windows by using the TBET/GATA3 ratio in
ACS.These studies should provide statistical confirmation of
the optimal cutoff value for the ratio. Secondly, it was not
possible to take samples at all the proposed time points which
in turn rendered statistical analysis difficult. This study was
conducted in a real-life context. Precise study conditions,
especially sampling, were curtailed because patients required
emergency therapeutic procedures. In order to proceed with
statistical analysis, missing data points were filled using a
statistical technique described by Snedecor andCochran [18].
In conclusion, this study has demonstrated that the
TBET/GATA3 mRNA ratio was elevated in patients with
AMI throughout most of the first 20 hours after onset of
acute symptoms.The biphasic M-shaped release kinetics was
more likely to reflect pathophysiological changes rather than
treatment effects.
Abbreviations
TBET: T-box expressed in T cells
GATA3: Guanine adenine thymine adenine
sequence-binding protein 3
ACS: Acute coronary syndrome
AMI: Acute myocardial infarction
Th: T-helper
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STEMI: ST elevation myocardial infarction
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428 Disease Markers
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